Indications for NAMENDA XR:

Moderate-to-severe dementia of the Alzheimer's type.

Adult:

Do not divide doses. Swallow whole or may open caps and sprinkle on applesauce, then consume entire contents. Initially 7mg once daily; titrate at intervals of at least 1 week in increments of 7mg to target dose of 28mg once daily. Max 28mg once daily. Severe renal impairment (CrCl 5–29mL/min): titrate to target dose of 14mg/day. Switching from immediate-release tabs: give XR caps the day after last dose of immediate-release tabs; see full labeling.

Children:

Not established.

See Also:

NAMENDA

NAMENDA ORAL SOLUTION

Pharmacological Class:

N-methyl-D-aspartate (NMDA) receptor antagonist.

Warnings/Precautions:

Severe hepatic impairment. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine serum levels. Seizure disorder. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, metformin, cimetidine, nicotine, ranitidine, quinidine). Plasma levels may be increased by urinary alkalinizers.

Adverse Reactions:

Headache, dizziness, confusion, diarrhea, constipation, hypertension, pain, somnolence, hallucination, urinary disorders, dyspnea.

Metabolism:

Hepatic (partial).

Elimination:

Renal.

How Supplied:

Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—360mL; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x 14mg + 7 x 21mg + 7 x 28mg)—1